ATE357914T1 - Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien - Google Patents

Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien

Info

Publication number
ATE357914T1
ATE357914T1 AT00911753T AT00911753T ATE357914T1 AT E357914 T1 ATE357914 T1 AT E357914T1 AT 00911753 T AT00911753 T AT 00911753T AT 00911753 T AT00911753 T AT 00911753T AT E357914 T1 ATE357914 T1 AT E357914T1
Authority
AT
Austria
Prior art keywords
aminopyridine
treat peripheral
peripheral neuropathies
treat
nervous system
Prior art date
Application number
AT00911753T
Other languages
English (en)
Inventor
Jay M Meythaler
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Application granted granted Critical
Publication of ATE357914T1 publication Critical patent/ATE357914T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT00911753T 1999-02-09 2000-02-09 Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien ATE357914T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11927399P 1999-02-09 1999-02-09

Publications (1)

Publication Number Publication Date
ATE357914T1 true ATE357914T1 (de) 2007-04-15

Family

ID=22383494

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00911753T ATE357914T1 (de) 1999-02-09 2000-02-09 Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien

Country Status (10)

Country Link
US (1) US6503931B1 (de)
EP (1) EP1152760B1 (de)
JP (1) JP2002536413A (de)
AT (1) ATE357914T1 (de)
AU (1) AU3360000A (de)
CA (1) CA2360326C (de)
DE (1) DE60034110T2 (de)
DK (1) DK1152760T3 (de)
ES (1) ES2284485T3 (de)
WO (1) WO2000047210A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2820423B1 (fr) * 2001-02-05 2005-12-02 Assist Publ Hopitaux De Paris Tartrate et phosphate de 3,4-diaminopyridine, compositions pharmaceutiques et utilisations
US20050192321A1 (en) * 2003-09-15 2005-09-01 Meythaler Jay M. Treatment of neuropathy with rapid release aminopyridine
CA2840591A1 (en) 2011-06-30 2013-01-03 Biomarin Pharmaceuticals, Inc. Methods of administering 3,4-diaminopyridine
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
US9993429B2 (en) 2013-03-15 2018-06-12 University Of Rochester Composition and methods for the treatment of peripheral nerve injury
MA35698B1 (fr) * 2013-05-16 2014-12-01 Univ Mohammed V Souissi Nouvelle composition du 3,4-diaminopyridin pour le traitement de la fatigabilité musculaire associée à des troubles neurovégétatifs.
WO2024011220A1 (en) 2022-07-08 2024-01-11 University Of Rochester Potassium channel blockers or derivatives thereof for preventing, alleviating, and/or treating tissue dysfunction caused by toxic insults

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221683A (en) * 1984-03-19 1993-06-22 The Rockefeller University Diaminopyridine compounds and methods of use
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
CA2085785C (en) * 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition

Also Published As

Publication number Publication date
WO2000047210A1 (en) 2000-08-17
DE60034110T2 (de) 2007-12-06
DE60034110D1 (de) 2007-05-10
EP1152760B1 (de) 2007-03-28
AU3360000A (en) 2000-08-29
JP2002536413A (ja) 2002-10-29
DK1152760T3 (da) 2007-07-30
US6503931B1 (en) 2003-01-07
EP1152760A1 (de) 2001-11-14
ES2284485T3 (es) 2007-11-16
CA2360326A1 (en) 2000-08-17
EP1152760A4 (de) 2005-03-23
CA2360326C (en) 2011-04-05

Similar Documents

Publication Publication Date Title
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE292971T1 (de) (s,s)-reboxetin zur behandlung von peripheren neuropathien
NZ335992A (en) Substituted pyrimidinone and pyridone compounds and methods of use
TR200101859T2 (tr) Kemokin alıcı aktivitesinin modülatörleri olarak N-üreidoalkil-piperidinler
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
UA66865C2 (uk) Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
DE69825440D1 (de) VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
ATE357914T1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
DE3481990D1 (de) Benzothiazol-2-sulfonamid-derivate, zur oertlichen behandlung von erhoehtem augeninnendruck.
ATE402694T1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz
DE69909257D1 (de) Verwendung von makroliden zur behandlung von akuten lungenverletzungen
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
GB9907048D0 (en) Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders
DE3784768T2 (de) Verwendung von zusammensetzungen auf basis von crotoxin, zur herstellung von medikamenten zur behandlung von carcinomen.
BR0112123A (pt) Composto
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
DE69926996D1 (de) Verwendung von riluzol zur behandlung der retinalischemie
ATE324111T1 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen
DE59506045D1 (de) Verwendung von substituierten 6-amino-4h-pyranen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties